Los tratamientos de linfocitos CAR-T son un enfoque prometedor para tratar tumores sólidos. Sin embargo, aún es un desafío identificar los dominios del receptor de linfocitos T (TCR) adecuados que se dirijan exclusivamente a los antígenos del tumor. Toxicity, tumor activation, and tumor persistence are significant challenges to using CAR-T cell therapies for solid tumors.In this webinar, Twist Bioscience’s CSO, Aaron Sato, will present several proof-of-concept studies showing how these technologies can be utilized for cell therapies. Aaron will also be joined by Justin Farlow, CTO of Serotiny, who will tell the story of how Twist’s Combinatorial Assembly Libraries helped his company design and evaluate thousands of CARs, each with novel intracellular signaling architectures. Al utilizar estas bibliotecas, Serotiny seleccionó rápidamente varios diseños de CAR novedosos para mejorar el rendimiento terapéutico de los linfocitos T primarios.